Skip to main content
Top
Published in: BMC Cardiovascular Disorders 1/2010

Open Access 01-12-2010 | Research article

The influence of heart disease on characteristics, quality of life, use of health resources, and costs of COPD in primary care settings

Authors: Javier de Miguel-Díez, Pilar Carrasco-Garrido, Javier Rejas-Gutierrez, Antonio Martín-Centeno, Elena Gobartt-Vázquez, Valentín Hernandez-Barrera, Angel Gil de Miguel, Rodrigo Jimenez-Garcia

Published in: BMC Cardiovascular Disorders | Issue 1/2010

Login to get access

Abstract

Background

To evaluate the influence of heart disease on clinical characteristics, quality of life, use of health resources, and costs of patients with COPD followed at primary care settings under common clinical practice conditions.

Methods

Epidemiologic, observational, and descriptive study (EPIDEPOC study). Patients ≥ 40 years of age with stable COPD attending primary care settings were included. Demographic, clinical characteristics, quality of life (SF-12), seriousness of the disease, and treatment data were collected. Results were compared between patients with or without associated heart disease.

Results

A total of 9,390 patients with COPD were examined of whom 1,770 (18.8%) had heart disease and 78% were males. When comparing both patient groups, significant differences were found in the socio-demographic characteristics, health profile, comorbidities, and severity of the airway obstruction, which was greater in patients with heart disease. Differences were also found in both components of quality of life, physical and mental, with lower scores among those patients with heart disease. Higher frequency of primary care and pneumologist visits, emergency-room visits and number of hospital admissions were observed among patients with heart diseases. The annual total cost per patient was significantly higher in patients with heart disease; 2,937 ± 2,957 vs. 1,749 ± 2,120, p < 0.05. Variables that were showed to be independently associated to COPD in subjects with hearth conditions were age, being inactive, ex-smokers, moderate physical exercise, body mass index, concomitant blood hypertension, diabetes, anxiety, the SF-12 physical and mental components and per patient per year total cost.

Conclusion

Patients with COPD plus heart disease had greater disease severity and worse quality of life, used more healthcare resources and were associated with greater costs compared to COPD patients without known hearth disease.
Literature
1.
go back to reference Peces-Barba G, Barberà JA, Agustí A, Casanova C, Casas A, Izquierdo JL, et al: Guía clínica SEPAR-ALAT de diagnóstico y tratamiento de la EPOC. Arch Bronconeumol. 2008, 44: 271-281. 10.1157/13119943.CrossRefPubMed Peces-Barba G, Barberà JA, Agustí A, Casanova C, Casas A, Izquierdo JL, et al: Guía clínica SEPAR-ALAT de diagnóstico y tratamiento de la EPOC. Arch Bronconeumol. 2008, 44: 271-281. 10.1157/13119943.CrossRefPubMed
2.
go back to reference Sobradillo Peña V, Miravitlles M, Gabriel R, Jiménez-Ruiz CA, Villasante C, Fernando Masa J, et al: Geographic variations in prevalence and underdiagnosis of COPD. Results of the IBERPOC multicentre epidemiological study. Chest. 2000, 118: 981-989. 10.1378/chest.118.4.981.CrossRef Sobradillo Peña V, Miravitlles M, Gabriel R, Jiménez-Ruiz CA, Villasante C, Fernando Masa J, et al: Geographic variations in prevalence and underdiagnosis of COPD. Results of the IBERPOC multicentre epidemiological study. Chest. 2000, 118: 981-989. 10.1378/chest.118.4.981.CrossRef
3.
go back to reference Menezes AM, Pérez-Padilla R, Jardim JR, Muino A, López MV, Valdivia G, et al: Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet. 2005, 366: 1875-1881. 10.1016/S0140-6736(05)67632-5.CrossRefPubMed Menezes AM, Pérez-Padilla R, Jardim JR, Muino A, López MV, Valdivia G, et al: Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet. 2005, 366: 1875-1881. 10.1016/S0140-6736(05)67632-5.CrossRefPubMed
4.
go back to reference Sydney S, Sorel M, Quesemberry CP, DeLuise C, Lanes S, Eisner MD: COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care. Chest. 2005, 128: 2068-2075. 10.1378/chest.128.4.2068.CrossRef Sydney S, Sorel M, Quesemberry CP, DeLuise C, Lanes S, Eisner MD: COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care. Chest. 2005, 128: 2068-2075. 10.1378/chest.128.4.2068.CrossRef
5.
go back to reference Holgin F, Folch E, Redd SC, Mannino DM: Comorbidity and mortality in COPD-related hospitalizations in the US, 1979 to 2001. Chest. 2005, 128: 2005-2011. 10.1378/chest.128.4.2005.CrossRef Holgin F, Folch E, Redd SC, Mannino DM: Comorbidity and mortality in COPD-related hospitalizations in the US, 1979 to 2001. Chest. 2005, 128: 2005-2011. 10.1378/chest.128.4.2005.CrossRef
6.
go back to reference Huiart L, Ernst P, Suissa S: Cardiovascular morbidity and mortality in COPD. Chest. 2005, 128: 2640-2646. 10.1378/chest.128.4.2640.CrossRefPubMed Huiart L, Ernst P, Suissa S: Cardiovascular morbidity and mortality in COPD. Chest. 2005, 128: 2640-2646. 10.1378/chest.128.4.2640.CrossRefPubMed
7.
go back to reference Hole DJ, Watt GC, Davey-Smith G, Hart CL, Gillis CR, Hawthorne VM: Impaired lung function and mortality risk in men and women from the Renfrew and Paisley prospective population study. BMJ. 1996, 313: 711-715.CrossRefPubMedPubMedCentral Hole DJ, Watt GC, Davey-Smith G, Hart CL, Gillis CR, Hawthorne VM: Impaired lung function and mortality risk in men and women from the Renfrew and Paisley prospective population study. BMJ. 1996, 313: 711-715.CrossRefPubMedPubMedCentral
8.
go back to reference Lung Health Study Research Group: Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med. 2000, 343: 1902-1909. 10.1056/NEJM200012283432601.CrossRef Lung Health Study Research Group: Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med. 2000, 343: 1902-1909. 10.1056/NEJM200012283432601.CrossRef
9.
go back to reference Villar Alvarez F, de Miguel Díez J, Álvarez-Sala JL: EPOC y acontecimientos cardiovasculares. Arch Bronconeumol. 2008, 44: 152-159.CrossRefPubMed Villar Alvarez F, de Miguel Díez J, Álvarez-Sala JL: EPOC y acontecimientos cardiovasculares. Arch Bronconeumol. 2008, 44: 152-159.CrossRefPubMed
10.
go back to reference Lusuardi M, Garuti G, Massobrio M, Spagnolatti L, Bendinelli S: Heart and lungs in COPD. Close friends in real life--separate in daily medical practice?. Monaldi Arch Chest Dis. 2008, 69: 11-17.PubMed Lusuardi M, Garuti G, Massobrio M, Spagnolatti L, Bendinelli S: Heart and lungs in COPD. Close friends in real life--separate in daily medical practice?. Monaldi Arch Chest Dis. 2008, 69: 11-17.PubMed
11.
go back to reference Herland K, Akselsen J, Skjonsberg OH, Bjermer L: How representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease?. Respir Med. 2005, 99: 11-19. 10.1016/j.rmed.2004.03.026.CrossRefPubMed Herland K, Akselsen J, Skjonsberg OH, Bjermer L: How representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease?. Respir Med. 2005, 99: 11-19. 10.1016/j.rmed.2004.03.026.CrossRefPubMed
12.
go back to reference Carrasco Garrido P, de Miguel Díez J, Rejas Gutiérrez J, Martín Centeno A, Gobartt Vázquez E, Gil de Miguel A, García Carballo M, Jiménez García R: Negative impact of chronic obstructive pulmonary disease on the health-related quality of life of patients. Results of the EPIDEPOC study. Health Qual Life Outcomes. 2006, 4: 31-10.1186/1477-7525-4-31.CrossRefPubMed Carrasco Garrido P, de Miguel Díez J, Rejas Gutiérrez J, Martín Centeno A, Gobartt Vázquez E, Gil de Miguel A, García Carballo M, Jiménez García R: Negative impact of chronic obstructive pulmonary disease on the health-related quality of life of patients. Results of the EPIDEPOC study. Health Qual Life Outcomes. 2006, 4: 31-10.1186/1477-7525-4-31.CrossRefPubMed
13.
go back to reference Chapman KR, Tashkin DP, Pye DJ: Gender bias in the diagnosis of COPD. Chest. 2001, 119: 1691-1695. 10.1378/chest.119.6.1691.CrossRefPubMed Chapman KR, Tashkin DP, Pye DJ: Gender bias in the diagnosis of COPD. Chest. 2001, 119: 1691-1695. 10.1378/chest.119.6.1691.CrossRefPubMed
14.
go back to reference Barberà JA, Peces-Barba G, Agustí AGN, Izquierdo JL, Monsó E, Montemayor T, Viejo JL, Sociedad Espanola de Neumologia y Cirugia Toracica (SEPAR): Guía clínica para el diagnóstico y el tratamiento de la enfermedad pulmonar obstructiva crónica. Arch Bronconeumol. 2001, 37: 297-316.CrossRefPubMed Barberà JA, Peces-Barba G, Agustí AGN, Izquierdo JL, Monsó E, Montemayor T, Viejo JL, Sociedad Espanola de Neumologia y Cirugia Toracica (SEPAR): Guía clínica para el diagnóstico y el tratamiento de la enfermedad pulmonar obstructiva crónica. Arch Bronconeumol. 2001, 37: 297-316.CrossRefPubMed
15.
go back to reference Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA: Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987, 106: 196-204.CrossRefPubMed Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA: Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987, 106: 196-204.CrossRefPubMed
16.
go back to reference Ware JE, Kosinski M, Keller SD: A 12-item short-form health survey. Construction of scales and preliminary tests of realiabity and validity. Med Care. 1996, 34: 220-233. 10.1097/00005650-199603000-00003.CrossRefPubMed Ware JE, Kosinski M, Keller SD: A 12-item short-form health survey. Construction of scales and preliminary tests of realiabity and validity. Med Care. 1996, 34: 220-233. 10.1097/00005650-199603000-00003.CrossRefPubMed
17.
go back to reference Vilagut G, Ferrer M, Rajmil L, Rebollo P, Permanyer-Miralda G, Quintana JM, et al: El cuestionario de salud SF-36 español: una década de experiencia y nuevos desarrollos. Gac Sanit. 2005, 19: 135-150. 10.1157/13074369.CrossRefPubMed Vilagut G, Ferrer M, Rajmil L, Rebollo P, Permanyer-Miralda G, Quintana JM, et al: El cuestionario de salud SF-36 español: una década de experiencia y nuevos desarrollos. Gac Sanit. 2005, 19: 135-150. 10.1157/13074369.CrossRefPubMed
18.
go back to reference Vilagut G, Ferrer M, Rajmil L, Rebollo P, Permanyer-Miralda G, Quintana JM, et al: El cuestionario de salud SF-36 español: una década de experiencia y nuevos desarrollos. Gac Sanit. 2005, 19: 135-150. 10.1157/13074369.CrossRefPubMed Vilagut G, Ferrer M, Rajmil L, Rebollo P, Permanyer-Miralda G, Quintana JM, et al: El cuestionario de salud SF-36 español: una década de experiencia y nuevos desarrollos. Gac Sanit. 2005, 19: 135-150. 10.1157/13074369.CrossRefPubMed
20.
go back to reference Van Manen JG, Bindels PJ, IJzermans CJ, Zee van der JS, Bottema BJ, Schade E: Prevalence of comorbidity in patients with a chronic airway obstruction and controls over the age of 40. J Clin Epidemiol. 2001, 54: 287-293. 10.1016/S0895-4356(01)00346-8.CrossRefPubMed Van Manen JG, Bindels PJ, IJzermans CJ, Zee van der JS, Bottema BJ, Schade E: Prevalence of comorbidity in patients with a chronic airway obstruction and controls over the age of 40. J Clin Epidemiol. 2001, 54: 287-293. 10.1016/S0895-4356(01)00346-8.CrossRefPubMed
21.
go back to reference Mapel DW, Hurley JS, Frost FJ, Petersen HV, Picchi MA, Coultas DB: Health care utilization in chronic obstructive pulmonary disease: a case-control study in a health maintenance organization. Arch Intern Med. 2000, 160: 2653-2658. 10.1001/archinte.160.17.2653.CrossRefPubMed Mapel DW, Hurley JS, Frost FJ, Petersen HV, Picchi MA, Coultas DB: Health care utilization in chronic obstructive pulmonary disease: a case-control study in a health maintenance organization. Arch Intern Med. 2000, 160: 2653-2658. 10.1001/archinte.160.17.2653.CrossRefPubMed
22.
go back to reference Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL: Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest. 2005, 128: 2099-2107. 10.1378/chest.128.4.2099.CrossRefPubMed Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL: Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest. 2005, 128: 2099-2107. 10.1378/chest.128.4.2099.CrossRefPubMed
23.
go back to reference Curkendall SM, DeLuise C, Jones JK, Lanes S, Stang MR, Goehring E, She D: Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol. 2006, 16: 63-70. 10.1016/j.annepidem.2005.04.008.CrossRefPubMed Curkendall SM, DeLuise C, Jones JK, Lanes S, Stang MR, Goehring E, She D: Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol. 2006, 16: 63-70. 10.1016/j.annepidem.2005.04.008.CrossRefPubMed
24.
go back to reference Falk JA, Kadiev S, Criner GJ, Scharf SM, Minai OA, Diaz P: Cardiac disease in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008, 5: 543-548. 10.1513/pats.200708-142ET.CrossRefPubMedPubMedCentral Falk JA, Kadiev S, Criner GJ, Scharf SM, Minai OA, Diaz P: Cardiac disease in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008, 5: 543-548. 10.1513/pats.200708-142ET.CrossRefPubMedPubMedCentral
25.
go back to reference Sin DD, Man SF: Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003, 107: 1514-1519. 10.1161/01.CIR.0000056767.69054.B3.CrossRefPubMed Sin DD, Man SF: Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003, 107: 1514-1519. 10.1161/01.CIR.0000056767.69054.B3.CrossRefPubMed
26.
go back to reference Antonelli-Incalzi R, Fuso L, De Rosa M, Forastiere F, Rapiti E, Nardecchia B, et al: Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J. 1997, 10: 2794-2800. 10.1183/09031936.97.10122794.CrossRefPubMed Antonelli-Incalzi R, Fuso L, De Rosa M, Forastiere F, Rapiti E, Nardecchia B, et al: Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J. 1997, 10: 2794-2800. 10.1183/09031936.97.10122794.CrossRefPubMed
27.
go back to reference Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Gallimore JR, Pepys MB: Low-grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ. 2000, 321: 199-204. 10.1136/bmj.321.7255.199.CrossRefPubMedPubMedCentral Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Gallimore JR, Pepys MB: Low-grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ. 2000, 321: 199-204. 10.1136/bmj.321.7255.199.CrossRefPubMedPubMedCentral
28.
go back to reference Ross R: Atherosclerosis: an inflammatory disease. N Engl J Med. 1999, 340: 115-126. 10.1056/NEJM199901143400207.CrossRefPubMed Ross R: Atherosclerosis: an inflammatory disease. N Engl J Med. 1999, 340: 115-126. 10.1056/NEJM199901143400207.CrossRefPubMed
29.
go back to reference Ridker PM: Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003, 107: 363-369. 10.1161/01.CIR.0000053730.47739.3C.CrossRefPubMed Ridker PM: Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003, 107: 363-369. 10.1161/01.CIR.0000053730.47739.3C.CrossRefPubMed
30.
go back to reference Wedzicha JA, Seemungal TA, MacCallum PK, Paul EA, Donaldson GC, Bhowmik A, et al: Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6. Thromb Haemost. 2000, 84: 210-215.PubMed Wedzicha JA, Seemungal TA, MacCallum PK, Paul EA, Donaldson GC, Bhowmik A, et al: Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6. Thromb Haemost. 2000, 84: 210-215.PubMed
31.
go back to reference Broekhuizen R, Wouters EF, Creutzberg EC, Schols AM: Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax. 2006, 61: 17-22. 10.1136/thx.2005.041996.CrossRefPubMed Broekhuizen R, Wouters EF, Creutzberg EC, Schols AM: Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax. 2006, 61: 17-22. 10.1136/thx.2005.041996.CrossRefPubMed
32.
go back to reference Pinto-Plata VM, Mullerova H, Toso JF, Feudjo-Tepie M, Soriano JB, Vessey RS, Celli BR: C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax. 2006, 61: 23-28. 10.1136/thx.2005.042200.CrossRefPubMed Pinto-Plata VM, Mullerova H, Toso JF, Feudjo-Tepie M, Soriano JB, Vessey RS, Celli BR: C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax. 2006, 61: 23-28. 10.1136/thx.2005.042200.CrossRefPubMed
33.
go back to reference Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG: C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007, 175: 250-255. 10.1164/rccm.200605-713OC.CrossRefPubMed Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG: C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007, 175: 250-255. 10.1164/rccm.200605-713OC.CrossRefPubMed
34.
go back to reference De Torres JP, Cordoba-Lanus E, López-Aguilar C, Muros de Fuentes M, Montejo de Garcini A, Aguirre-Jaime A, et al: C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J. 2006, 27: 902-907.PubMed De Torres JP, Cordoba-Lanus E, López-Aguilar C, Muros de Fuentes M, Montejo de Garcini A, Aguirre-Jaime A, et al: C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J. 2006, 27: 902-907.PubMed
35.
go back to reference Lagrand WK, Visser CA, Hermens WT, Niessen HW, Verheugt FW, Wolbink GJ, et al: C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon?. Circulation. 1999, 100: 96-102.CrossRefPubMed Lagrand WK, Visser CA, Hermens WT, Niessen HW, Verheugt FW, Wolbink GJ, et al: C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon?. Circulation. 1999, 100: 96-102.CrossRefPubMed
36.
go back to reference Salpeter S, Ormiston T, Salpeter E: Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004, 125: 2309-2321. 10.1378/chest.125.6.2309.CrossRefPubMed Salpeter S, Ormiston T, Salpeter E: Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004, 125: 2309-2321. 10.1378/chest.125.6.2309.CrossRefPubMed
37.
go back to reference Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J, TORCH Investigators: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007, 356: 775-789. 10.1056/NEJMoa063070.CrossRefPubMed Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J, TORCH Investigators: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007, 356: 775-789. 10.1056/NEJMoa063070.CrossRefPubMed
38.
go back to reference Huerta C, Lanes SF, Garcia Rodriguez LA: Respiratory medications and the risk of cardiac arrhythmias. Epidemiology. 2005, 16: 360-366. 10.1097/01.ede.0000158743.90664.a7.CrossRefPubMed Huerta C, Lanes SF, Garcia Rodriguez LA: Respiratory medications and the risk of cardiac arrhythmias. Epidemiology. 2005, 16: 360-366. 10.1097/01.ede.0000158743.90664.a7.CrossRefPubMed
39.
go back to reference Hooft Van der CS, Heeringa J, Brusselle GG, Hofman A, Witteman JC, Kingma JH, Sturkenboom MC, Stricker BH: Corticosteroids and the risk of atrial fibrillation. Arch Intern Med. 2006, 166: 1016-1020. 10.1001/archinte.166.9.1016.CrossRefPubMed Hooft Van der CS, Heeringa J, Brusselle GG, Hofman A, Witteman JC, Kingma JH, Sturkenboom MC, Stricker BH: Corticosteroids and the risk of atrial fibrillation. Arch Intern Med. 2006, 166: 1016-1020. 10.1001/archinte.166.9.1016.CrossRefPubMed
40.
go back to reference Ferrer M, Alonso J, Morera J, Marrades RM, Khalaf A, Aguar MC, et al: Chronic obstructive pulmonary disease stage and health-related quality of life. Ann Intern Med. 1997, 127: 1072-1079.CrossRefPubMed Ferrer M, Alonso J, Morera J, Marrades RM, Khalaf A, Aguar MC, et al: Chronic obstructive pulmonary disease stage and health-related quality of life. Ann Intern Med. 1997, 127: 1072-1079.CrossRefPubMed
41.
go back to reference Van Manen JG, Bindels PJ, Dekker EW, Ijzermans CJ, Bottema BJ, Zee van der JS, et al: Added value of co-morbidity in predicting health-related quality of life in COPD patients. Respir Med. 2001, 95: 496-504. 10.1053/rmed.2001.1077.CrossRefPubMed Van Manen JG, Bindels PJ, Dekker EW, Ijzermans CJ, Bottema BJ, Zee van der JS, et al: Added value of co-morbidity in predicting health-related quality of life in COPD patients. Respir Med. 2001, 95: 496-504. 10.1053/rmed.2001.1077.CrossRefPubMed
42.
go back to reference Oostenbrink J, Rutten-van Molken M: Resource use and risk factors in high-cost exacerbations of COPD. Respir Med. 2004, 98: 883-91. 10.1016/j.rmed.2004.02.013.CrossRefPubMed Oostenbrink J, Rutten-van Molken M: Resource use and risk factors in high-cost exacerbations of COPD. Respir Med. 2004, 98: 883-91. 10.1016/j.rmed.2004.02.013.CrossRefPubMed
43.
go back to reference Mannino DM, Watt G, Hole D, Gillis C, Hart C, McConnachie A, et al: The natural history of chronic obstructive pulmonary disease. Eur Respir J. 2006, 27: 627-643. 10.1183/09031936.06.00024605.CrossRefPubMed Mannino DM, Watt G, Hole D, Gillis C, Hart C, McConnachie A, et al: The natural history of chronic obstructive pulmonary disease. Eur Respir J. 2006, 27: 627-643. 10.1183/09031936.06.00024605.CrossRefPubMed
44.
go back to reference Yeo Y, Karimova G, Bansal S: Co-morbidity in older patients with COPD - its impacto on health service utilisation and quality of life, a community study. Age and Ageing. 2006, 35: 33-37. 10.1093/ageing/afj002.CrossRefPubMed Yeo Y, Karimova G, Bansal S: Co-morbidity in older patients with COPD - its impacto on health service utilisation and quality of life, a community study. Age and Ageing. 2006, 35: 33-37. 10.1093/ageing/afj002.CrossRefPubMed
45.
go back to reference De Miguel Díez J, Carrasco Garrido P, García Carballo M, Gil de Miguel A, Rejas Gutierrez J, Bellón Cano JM, et al: Determinants and predictors of the cost of COPD in primary care: a Spanish perspective. Int J Chron Obstruct Pulmon Dis. 2008, 3: 701-712.PubMedPubMedCentral De Miguel Díez J, Carrasco Garrido P, García Carballo M, Gil de Miguel A, Rejas Gutierrez J, Bellón Cano JM, et al: Determinants and predictors of the cost of COPD in primary care: a Spanish perspective. Int J Chron Obstruct Pulmon Dis. 2008, 3: 701-712.PubMedPubMedCentral
46.
go back to reference Sicras Mainar A, Navarro Artieda R, Fernández de Bobadilla J, García Vargas M: Estimation of the presence of cardiovascular events and direct costs associated with chronic obstructive pulmonary disease in an ambulatory setting. Med Clin (Barc). 2007, 128: 317-8. 10.1016/S0025-7753(07)72573-3.CrossRef Sicras Mainar A, Navarro Artieda R, Fernández de Bobadilla J, García Vargas M: Estimation of the presence of cardiovascular events and direct costs associated with chronic obstructive pulmonary disease in an ambulatory setting. Med Clin (Barc). 2007, 128: 317-8. 10.1016/S0025-7753(07)72573-3.CrossRef
47.
go back to reference Marco JL, Martin Berra JC, Corres IM, Luque DR, Zubillaga GG: [Chronic obstructive lung disease in the general population. An epidemiologic study performed in Guipuzcoa]. Spanish. ArchBronconeumol. 1998, 34: 23-27. Marco JL, Martin Berra JC, Corres IM, Luque DR, Zubillaga GG: [Chronic obstructive lung disease in the general population. An epidemiologic study performed in Guipuzcoa]. Spanish. ArchBronconeumol. 1998, 34: 23-27.
48.
go back to reference Brotons B, Perez JA, Sanchez-Toril F, Soriano S, Hernandez J, Belenguer JL: [The prevalence of chronic obstructive pulmonary disease and asthma. A cross-sectional study]. Spanish. Arch Bronconeumol. 1994, 30: 149-152.CrossRefPubMed Brotons B, Perez JA, Sanchez-Toril F, Soriano S, Hernandez J, Belenguer JL: [The prevalence of chronic obstructive pulmonary disease and asthma. A cross-sectional study]. Spanish. Arch Bronconeumol. 1994, 30: 149-152.CrossRefPubMed
Metadata
Title
The influence of heart disease on characteristics, quality of life, use of health resources, and costs of COPD in primary care settings
Authors
Javier de Miguel-Díez
Pilar Carrasco-Garrido
Javier Rejas-Gutierrez
Antonio Martín-Centeno
Elena Gobartt-Vázquez
Valentín Hernandez-Barrera
Angel Gil de Miguel
Rodrigo Jimenez-Garcia
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2010
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/1471-2261-10-8

Other articles of this Issue 1/2010

BMC Cardiovascular Disorders 1/2010 Go to the issue